Published
June 26, 2026
What’s Happening
The Inflation Reduction Act’s (IRA’s) drug pricing negotiation program determines which medicines may be subject to government price setting. The statute is meant to evaluate a medicine based on its own approval, its own characteristics, and whether meaningful competition exists.
But bureaucrats at CMS have taken a broader approach. Instead of looking at each medicine on its own merits, the agency is treating distinct medicines that share the same core ingredient as though they are essentially the same product. This seemingly small change could have significant consequences for patients, caregivers, and the innovators.
Why It Matters to Patients
Most people think medical innovation happens at one moment: when a new medicine is first approved. In reality, that is often just the beginning.
After an initial approval, scientists continue to improve medicines in ways that can make a real difference in patients’ lives. They may discover new uses, improve safety, reduce side effects, develop more convenient dosing, or create new ways to deliver treatment. Those advances can mean everything from shorter treatment times to fewer hospital or clinic visits.
These are the improvements that make care more manageable in the real world. But under CMS’s current approach, many of these meaningful advancements could be treated as if they are no different from the original medicine. Specifically, the rule that CMS is now pursuing fails to acknowledge the additional innovation and patient benefit that come from unique combination drugs when those drugs create opportunities for more convenient dosing, less time in the clinic, and lessened burdens on caregivers.
The Unintended Consequence
When policy treats real improvements like duplicates, it sends a clear message to innovators: do not invest. That is the danger. Many advances patients value most are precisely the kinds of improvements CMS’s interpretation could discourage. A new formulation, delivery method, or treatment approach may not always look dramatic on paper, but for a patient it can be life changing.
If innovative companies know that any additional breakthrough may quickly be swept into price setting simply because it shares a core ingredient with an earlier medicine, the investment case becomes much harder to make. Over time, that means fewer new options for patients.
Left unchanged, CMS’s proposed policy risks pushing companies away from developing improved treatments and cures that could save lives.
The Bottom Line
Policies like this do not just affect prices. They shape what gets invented in the first place. CMS should return to a clearer, more straightforward approach that evaluates each medicine on its own merits.
About the author
Brad Watts
Brad Watts is the Senior Vice President at the U.S. Chamber of Commerce's Global Innovation Policy Center (GIPC). He works with U.S. Chamber members to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
